X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Elder Pharma with Merck Ltd - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ELDER PHARMA vs MERCK LTD - Comparison Results

MERCK LTD 
   Change

Merck, the Indian arm of Merck KgaA (Germany), is a relatively smaller player among MNC pharma majors in the country. Merck has two business segments namely Pharmaceuticals and Chemicals. The pharmaceutical business, accounting for 68% of total sales... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ELDER PHARMA MERCK LTD ELDER PHARMA/
MERCK LTD
 
P/E (TTM) x -0.2 26.1 - View Chart
P/BV x 0.1 2.9 3.5% View Chart
Dividend Yield % 0.0 1.0 -  

Financials

 ELDER PHARMA   MERCK LTD
EQUITY SHARE DATA
    ELDER PHARMA
Jun-14
MERCK LTD
Dec-16
ELDER PHARMA/
MERCK LTD
5-Yr Chart
Click to enlarge
High Rs3801,060 35.8%   
Low Rs188623 30.2%   
Sales per share (Unadj.) Rs491.2632.4 77.7%  
Earnings per share (Unadj.) Rs-3.245.7 -7.0%  
Cash flow per share (Unadj.) Rs14.462.3 23.1%  
Dividends per share (Unadj.) Rs011.00 0.0%  
Dividend yield (eoy) %01.3 0.0%  
Book value per share (Unadj.) Rs376.5388.8 96.8%  
Shares outstanding (eoy) m20.5416.60 123.7%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x0.61.3 43.5%   
Avg P/E ratio x-89.318.4 -484.9%  
P/CF ratio (eoy) x19.713.5 146.0%  
Price / Book Value ratio x0.82.2 34.9%  
Dividend payout %024.1 0.0%   
Avg Mkt Cap Rs m5,83313,969 41.8%   
No. of employees `000NA1.6 0.0%   
Total wages/salary Rs m2,1791,487 146.6%   
Avg. sales/employee Rs ThNM6,631.9-  
Avg. wages/employee Rs ThNM939.2-  
Avg. net profit/employee Rs ThNM479.4-  
INCOME DATA
Net Sales Rs m10,08910,498 96.1%  
Other income Rs m257242 105.9%   
Total revenues Rs m10,34610,741 96.3%   
Gross profit Rs m-7921,135 -69.8%  
Depreciation Rs m361276 131.1%   
Interest Rs m2,7560-   
Profit before tax Rs m-3,6531,102 -331.4%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m3,7130-   
Tax Rs m125343 36.5%   
Profit after tax Rs m-65759 -8.6%  
Gross profit margin %-7.810.8 -72.6%  
Effective tax rate %-3.431.1 -11.0%   
Net profit margin %-0.67.2 -9.0%  
BALANCE SHEET DATA
Current assets Rs m9,2406,410 144.2%   
Current liabilities Rs m9,9988,828 113.2%   
Net working cap to sales %-7.5-23.0 32.6%  
Current ratio x0.90.7 127.3%  
Inventory Days Days4658 80.3%  
Debtors Days Days6038 156.1%  
Net fixed assets Rs m10,1241,406 719.8%   
Share capital Rs m206166 123.9%   
"Free" reserves Rs m5,5826,286 88.8%   
Net worth Rs m7,7346,455 119.8%   
Long term debt Rs m4,8890-   
Total assets Rs m22,8828,828 259.2%  
Interest coverage x-0.3NM-  
Debt to equity ratio x0.60-  
Sales to assets ratio x0.41.2 37.1%   
Return on assets %11.88.6 136.8%  
Return on equity %-0.811.8 -7.2%  
Return on capital %22.317.1 130.7%  
Exports to sales %3.08.3 36.7%   
Imports to sales %0.421.0 2.0%   
Exports (fob) Rs m307869 35.3%   
Imports (cif) Rs m432,209 2.0%   
Fx inflow Rs m307959 32.0%   
Fx outflow Rs m1252,612 4.8%   
Net fx Rs m181-1,653 -11.0%   
CASH FLOW
From Operations Rs m11,7541,070 1,098.1%  
From Investments Rs m-561-750 74.8%  
From Financial Activity Rs m-6,762-150 4,513.9%  
Net Cashflow Rs m4,432171 2,593.2%  

Share Holding

Indian Promoters % 39.6 0.0 -  
Foreign collaborators % 0.0 51.8 -  
Indian inst/Mut Fund % 7.5 18.2 41.2%  
FIIs % 16.8 1.0 1,680.0%  
ADR/GDR % 0.0 0.0 -  
Free float % 36.1 29.1 124.1%  
Shareholders   16,479 28,591 57.6%  
Pledged promoter(s) holding % 77.6 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ELDER PHARMA With:   ASTRAZENECA PHARMA  ALEMBIC PHARMA  CADILA HEALTHCARE  NOVARTIS  DR. DATSONS LABS  

Compare ELDER PHARMA With:   MYLAN (US)  ADCOCK INGRAM (S. Africa)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Weak Finish to the Week Post Vishal Sikka's Exit as CEO of Infosys(Closing)

Share markets in India witnessed selling pressure, led by slump in shares of Infosys Ltd. after Vishal Sikka resigned as chief executive officer of the country's second-largest software services exporter.

Related Views on News

Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

Aug 14, 2017

A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

Aug 14, 2017

GST impact coupled with price erosion in US leads to lower profits for the quarter.

Dr Reddy's: US Pressure Continues to Haunt (Quarterly Results Update - Detailed)

Aug 8, 2017

Profits plunge due to higher raw material costs.

Biocon: Lower Licensing Income Leads to Muted Growth for the Quarter (Quarterly Results Update - Detailed)

Jun 23, 2017

Net Profit lower due to exceptional items in the previous year.

The Power of 5 Minutes (The 5 Minute Wrapup)

Jun 16, 2017

Here's what you can expect from The 5 Minute Wrapup in the coming months and years.

More Views on News

Most Popular

Demonetisation Barely Made Any Difference to Tax Collections(Vivek Kaul's Diary)

Aug 7, 2017

The data tells us quite a different story from the one the government is trying to project.

A 'Backdoor' to Multibaggers: It's Like Investing in Asian Paints Ten Years Ago(The 5 Minute Wrapup)

Aug 10, 2017

Don't miss these proxy bets on growing companies or in a few years you will be looking back with regret.

Should You Invest In Bharat-22 ETF? Know Here...(Outside View)

Aug 8, 2017

Bharat-22 is one of the most diverse ETFs offered so far by the Government. Know here if you should invest...

Signs of Life in the India VIX(Daily Profit Hunter)

Aug 12, 2017

The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.

7 Financial Gifts For Your Sister This Raksha Bandhan(Outside View)

Aug 7, 2017

Raksha Bandhan signifies the brother-sister bond. Here are 7 thoughtful financial gifts for sisters...

More

Become A Smarter Investor In
Just 5 Minutes

Multibagger Stocks Guide 2017
Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

ELDER PHARMA SHARE PRICE


Sep 12, 2016 (Close)

TRACK ELDER PHARMA

  • Track your investment in ELDER PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

ELDER PHARMA 8-QTR ANALYSIS

COMPARE ELDER PHARMA WITH

MARKET STATS